Prithviraj Bose
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Prithviraj Bose as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04517851 · Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisM.D. Anderson Cancer Center · active not recruiting · Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis · principal investigator
- Ph2NCT03019939 · Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and NeutropeniaM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Neutropenia · principal investigator
- Ph2/Ph3NCT02801578 · A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02784496 · Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisM.D. Anderson Cancer Center · completed · Myelofibrosis · principal investigator
- Ph1NCT02782403 · Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaM.D. Anderson Cancer Center · terminated · Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase Chronic Myelogenous Leukemia (CML) · principal investigator
- Ph2NCT01712308 · Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaM.D. Anderson Cancer Center · completed · Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:05 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed
- Ibrutinib and Venetoclax for First-Line Treatment of CLL.N Engl J Med · 2019426 citationsRCR 15.0
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.Nat Med · 2021146 citationsRCR 9.4
- A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.Blood Cancer Discov · 2023128 citationsRCR 11.1
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J · 2021120 citationsRCR 6.8
- Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.Clin Lymphoma Myeloma Leuk · 2020118 citationsRCR 5.1
- 114 citationsRCR 4.4
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.Lancet Haematol · 2019113 citationsRCR 4.0
- Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.JAMA Oncol · 2021102 citationsRCR 5.1